Published in PLoS One on July 18, 2017
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem (1996) 7.23
AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays (2001) 4.07
New roles for the LKB1-->AMPK pathway. Curr Opin Cell Biol (2005) 2.36
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci (2004) 1.89
TGFbeta pathobiology in the eye. Lab Invest (2006) 1.85
Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem (2009) 1.56
AMPKα2 reduces renal epithelial transdifferentiation and inflammation after injury through interaction with CK2β. J Pathol (2015) 1.40
Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res (1999) 1.38
Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest Ophthalmol Vis Sci (2007) 1.37
Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A (2008) 1.31
5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun (2004) 1.29
Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (1999) 1.28
Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J Biol Chem (2001) 1.27
Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol (2013) 1.24
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4-carboxamide riboside is independent of AMP-activated protein kinase. J Cell Biochem (2008) 1.24
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (1994) 1.18
A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (1998) 1.15
Human massive periretinal proliferation. In vitro characteristics of cellular components. Arch Ophthalmol (1981) 1.07
HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis (2002) 1.03
Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem (2013) 1.03
Epithelial-mesenchymal transition as a therapeutic target for prevention of ocular tissue fibrosis. Endocr Metab Immune Disord Drug Targets (2008) 1.02
Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells. Lab Invest (2005) 1.01
Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci (2009) 1.00
Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells. Invest Ophthalmol Vis Sci (2002) 1.00
Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathways. PLoS One (2013) 0.99
Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol (2013) 0.98
AMP-activated protein kinase suppresses matrix metalloproteinase-9 expression in mouse embryonic fibroblasts. J Biol Chem (2011) 0.97
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm (2012) 0.96
AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol (2013) 0.93
Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med (2014) 0.93
Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One (2014) 0.93
Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels. Invest Ophthalmol Vis Sci (1993) 0.91
Mechanisms of epithelial-mesenchymal transition in proliferative vitreoretinopathy. Discov Med (2015) 0.87
Implication of S-adenosylhomocysteine hydrolase in inhibition of TNF-alpha- and IL-1beta-induced expression of inflammatory mediators by AICAR in RPE cells. Invest Ophthalmol Vis Sci (2008) 0.87
Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol (2006) 0.86
Effect of berberine on proinflammatory cytokine production by ARPE-19 cells following stimulation with tumor necrosis factor-α. Invest Ophthalmol Vis Sci (2012) 0.82
Proliferative vitreoretinopathy. Br J Ophthalmol (1995) 0.82
Enhanced PKCδ and ERK signaling mediate cell migration of retinal pigment epithelial cells synergistically induced by HGF and EGF. PLoS One (2012) 0.81
AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition. Mol Pharmacol (2015) 0.81
Inhibition of the TNF-α-induced serine phosphorylation of IRS-1 at 636/639 by AICAR. J Pharmacol Sci (2013) 0.78
Autologous transplantation of the internal limiting membrane for refractory macular holes. Am J Ophthalmol (2014) 1.03
Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol (2014) 0.96
Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol (2015) 0.93
Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol (2014) 0.78
Factors Affecting Choroidal Vascular Density in Normal Eyes: Quantification Using En Face Swept-Source Optical Coherence Tomography. Am J Ophthalmol (2016) 0.77
COL4A6 is dispensable for autosomal recessive Alport syndrome. Sci Rep (2016) 0.75
Factors affecting foveal avascular zone in healthy eyes: An examination using swept-source optical coherence tomography angiography. PLoS One (2017) 0.75
Assessment of tilt and decentration of crystalline lens and intraocular lens relative to the corneal topographic axis using anterior segment optical coherence tomography. PLoS One (2017) 0.75
Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients. Acta Ophthalmol (2016) 0.75
Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study. Br J Ophthalmol (2019) 0.75
COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina (2015) 0.75
Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists. Jpn J Ophthalmol (2016) 0.75
Planned Foveal Detachment Technique for the Resolution of Diabetic Macular Edema Resistant to Anti-Vascular Endothelial Growth Factor Therapy. Retina (2017) 0.75